Phase 2 Study for C3G and MPGN patients
A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Breve descripción
This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN
Médico del ensayo/Coordinador del estudio
Clinical Trial Team
Correo electrónico Número de teléfono 203-752-5566Nombre del sitio
Stanford University
Nombre del patrocinador
Achillion Pharmaceuticals
Nombre del fármaco del estudio
ACH-0144471
Matrícula estimada
20
Fecha estimada de finalización
May, 2020
Phase 2 Study for C3G and MPGN patients
A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Breve descripción
This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN
El ensayo es para personas con
C3 Glomerulonephritis / C3 Glomerulopathy (C3G) or Immune Complex Membranoproliferative Glomerulonephritis
(IC-MPGN)
Objetivo del estudio
This study will look at the whether the study drug is improving symptoms through a renal biopsy.
Qué implica para el paciente?
Patients will participate for 1 year. Additional study visits and diagnostic tests may be required, including biopsies and labwork.
Sobre el medicamento o la intervención
ACH-0144471 is an oral tablet that study participants will take daily.